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OVERVIEW
It is generally accepted that the flow of genetic informa-
tion from genomic DNA to functional protein is not unidi-
rectional and linear. Rather, numerous molecular pathways 
regulate the processes of replication, transcription, and 
translation to fine-tune the output of protein-coding genes. 
Specifically, RNA interference is a biological process in 
which specialized small RNAs—short interfering RNAs 
(siRNAs) or microRNAs (miRNAs)—posttranscriptionally reg-
ulate the expression of specific target genes. In the December 
2013 Research Techniques Made Simple, Nambudiri and 
Widlund described siRNAs and applications in investigative 
dermatology (Nambudiri and Widlund, 2013). Here, we out-
line how miRNAs modulate expression of genes relevant to 
skin pathology by inhibiting protein translation.
INTRODUCTION
miRNAs are short (~22-nucleotide) double-stranded RNAs 
that mediate key biological and developmental processes 
by binding with imperfect complementarity to specific sites 
within their target genes to induce repression of gene expres-
sion. The mechanism of various miRNAs’ actions is similar, 
irrespective of the nucleotide sequence or the gene target. 
miRNAs are thought to regulate more than a third of all genes 
(Lewis et al., 2005), and they may exert their effects in a coor-
dinate fashion; that is, multiple miRNAs may target and regu-
late a single, specific gene transcript (Figure 1a). Conversely, 
a single miRNA can bind to and repress the expression of 
hundreds or even thousands of target transcripts (Figure 1b), 
enabling miRNAs to simultaneously regulate multiple genes 
within a single physiological pathway (Webster et al., 2009). 
THE DISCOVERY
In a landmark discovery, Lee and co-workers identified that 
lin-4, a gene critically implicated in Caenorhabditis elegans 
larval development, does not code for a protein but rather 
controls the expression of RNA species, one of which is of 
22-nucleotide base length. Crucially, the group found that 
lin-4 RNAs had antisense complementarity to multiple sites 
in the 3′ untranslated region (3′ UTR) of the lin-14 mRNA 
(Lee et al., 1993) that had earlier been suggested to control 
lin-14 expression (Ambros, 1989). Furthermore, LIN-14 pro-
tein levels were found to be inversely proportional to those 
of lin-4 RNA, suggesting that as a regulatory small RNA (a 
miRNA), lin-4 might regulate LIN-14 protein expression dur-
WHAT miRNAs DO
•  miRNAs modulate transcription and repress 
translation, providing a level of control before the 
production of protein can exert biological effects.
•  A single miRNA can have multiple targets, 
potentially providing simultaneous regulation of 
many genes involved in a physiological pathway.
•  Multiple miRNAs with the same target reinforce the 
developmental program via redundant effectors of 
regulation.
LIMITATIONS
•  Delivery: Because miRNAs do not freely diffuse into 
cells, special delivery approaches may be needed 
for both experimental and therapeutic design.
•  Instability: Small RNAs are unstable and may be 
degraded upon entering a cell.
•  Off-target effects: miRNA therapy can target 
an array of different gene products, with the 
possibility of undesired effects.
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Figure 1.  Mode of action of microRNAs.  (a) Multiple miRNAs can 
work together to target and regulate a single, specific gene transcript in a 
coordinate fashion, thereby reinforcing the developmental program via 
redundant effectors of regulation. (b) A single miRNA can have multiple 
mRNA targets, potentially providing simultaneous and powerful control of a 
single physiological pathway by regulation of multiple target genes relevant 
to that process (e.g., proteins A, B, and C).
research Techniques made simple  
2 Journal of Investigative Dermatology (2015), Volume 135 © 2015 The Society for Investigative Dermatology
ment of adapter proteins and deadenylase complex, which 
deadenylates the transcript (breaking down the poly-A tail) to 
inhibit translation initiation. Alternatively, less extensive base 
pairing can halt mRNA translation if the minimum binding 
requirement, known as the 7-base seed sequence, between 
the miRNA and the 3′ UTR of the target mRNA is fulfilled. 
In this manner, miRNAs may act as a “brake” to upregulated 
cellular responses by modulating both mRNA and protein 
levels of effector molecules critical to these processes.
IDENTIFICATION OF miRNA TARGETS 
There are four steps required for the identification of miRNAs 
and their subsequent physiologic characterization (Figure 
3). First, expression profiling of miRNAs is accomplished 
with miRNA arrays or quantitative RT-PCR assays designed 
to detect and accurately quantify mature miRNAs in genet-
ic material extracted from cell lines or tissue. Second, after 
miRNA expression profiling produces the data set of dif-
ferentially regulated miRNAs (e.g., between control and 
diseased tissue), target prediction analysis follows to iden-
tify candidate gene targets for individual miRNAs of interest. 
This is accomplished using computational methods such as 
TargetScan (http://www.targetscan.org) or miRBase (http://
www.mirbase.org). These database tools predict biological 
targets of miRNAs by searching for the presence of sites that 
match the seed region of each miRNA. Third, in vitro target 
validation, by a luciferase reporter assay, confirms the func-
tional ability of a given miRNA to bind to the predicted 3′ 
UTR target sequence and repress protein production (as indi-
cated by a decreased reporter signal) (Figure 4). Mutations in 
the 3′ UTR luciferase reporter would abrogate any changes 
in reporter gene expression induced by cotransfection of an 
miRNA targeting the site of interest. Fourth, phenotypic con-
firmation is used to functionally characterize the miRNA–
mRNA interaction using methods of protein detection, such 
as western blotting. miRNAs are transfected into cells to turn 
down protein production, detected by a band of decreased 
intensity on a western blot. This effect can be reversed by 
ing development. Together, these discoveries suggested a 
model in which lin-4, the first characterized miRNA, binds 
to the lin-14 3′ UTR of mRNA in a complementary fashion 
to dictate translational repression of the lin-14 transcript and 
control the basic biology of nematode development. More 
recently, many miRNAs have been found to be conserved 
across species, including humans, and there is an ever-
increasing awareness of and interest in the critical roles that 
they play in controlling both normal and disease physiology, 
including many diverse areas of medicine such as cancer 
biology, cardiology, and dermatology.
miRNA BIOGENESIS, PROCESSING, AND TARGET 
RECOGNITION
miRNA biogenesis involves a sequential series of processes, 
each of which can be tightly regulated within a given cell. 
miRNA genes, contained within the introns of other genes 
(intragenic) or in intergenic regions, are transcribed by RNA 
polymerase II to produce a long primary RNA transcript (pri-
miRNA). With base complementarity, the pri-miRNA tran-
script forms a hairpin that is then sequentially processed by 
Drosha/Pasha (Dgcr8) in the nucleus to produce a precursor 
miRNA (pre-miRNA) hairpin, which is next exported from 
the nucleus by the exportin 5 complex. Once in the cyto-
plasm, Dicer cleaves the pre-miRNA hairpin loop (Lee et al., 
2003). One strand of the miRNA duplex (the “guide” strand) 
loads on the argonaute protein, forming the miRNA silenc-
ing complex, which targets specific mRNAs by two proposed 
mechanisms of action: mRNA destabilization and decay or 
translational repression (Figure 2).
 One of the factors that determine whether an miRNA tar-
gets a specific mRNA is the degree of complementarity in 
base pairing between miRNA and mRNA. Extensive pairing 
between the miRNA and mRNA-3′ UTR typically induces 
mRNA destabilization, thereby altering the cell’s transcrip-
tional profile. mRNA destabilization occurs through recruit-
RESEARCH ECHNI UES MADE SIMPLE
Figure 2.  MicroRNA processing.  MicroRNAs are sequentially processed in 
both the nucleus (DROSHA/PASHA) and the cytoplasm (Dicer). After the pre-
miRNA hairpin is exported from the nucleus by exportin 5, Dicer cleaves the 
hairpin loop. The miRNA silencing complex (miRNA and argonaute protein) 
targets specific mRNAs at the 3′ untranslated region (3′ UTR) and modifies 
protein expression by two mechanisms: mRNA destabilization and decay or 
translational repression. The deadenylase complex (deA) deadenylates the 
transcript by removal of the poly-A tail. This destabilizes the mRNA and also 
inhibits translation initiation.
Figure 3.  Four steps for miRNA identification and characterization.  (1) 
miRNA identification is accomplished with miRNA arrays or quantitative 
RT-PCR assays. (2) Target prediction uses computational methods such 
as TargetScan or miRBase. (3) Target validation, by a luciferase reporter 
assay, highlights the functional ability of miRNA to bind to the predicted 3′ 
untranslated region (3′ UTR) target sequence and repress protein production 
(decreased signal). (4) Phenotypic confirmation is performed by western 
blots, which detect the level of proteins. miRNAs (miR), which turn down 
protein production, would decrease the band intensity (lane 2). This can 
be reversed by anti-microRNAs (anti-miR) or antagomiRs, oligonucleotides 
designed to antagonize the role of miRNAs through antisense 
complementary base pairing (lane 4).
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anti-microRNAs, or antagomiRs, oligonucleotides designed 
to antagonize the activity of a given miRNA through anti-
sense complementary base pairing.
RELEVANCE OF miRNAS TO DERMATOLOGY
miRNAs are critical both for the normal development of the 
integumentary system and in diseases involving the skin. 
Initial investigations of the role of miRNAs in skin focused at 
the level of miRNA biogenesis and processing. Because the 
essential enzymes Dicer and Dgcr are inextricably linked to 
miRNA processing (Figure 2; see also “miRNA Biogenesis, 
Processing, and Target Recognition” above), their loss led 
to global depletion of miRNAs. Because mice that constitu-
tively lacked Dicer or Dgcr8 died during early embryogen-
esis, before the development of the integumentary system, 
the Cre-loxP technology was employed to restrict the loss 
of these components to the skin alone at later stages. Under 
the control of the keratin 14 promoter, which is expressed 
specifically in the basal layer of the epidermis, epidermal-
specific deletion of Dicer or Dgcr8 in embryonic skin pro-
genitors in murine models perturbed epidermal organization, 
dermal papillae formation, and the architecture of the devel-
oping hair follicle, emphasizing the importance of miRNAs 
in morphogenesis (Yi et al., 2006, 2009). More recently, spe-
cific miRNAs were identified as playing a role in the develop-
ing skin. The epithelium is both stratified and dynamic, with 
deeper stem cells differentiating, becoming suprabasal, and 
requiring miRNA control. Specifically, miR-203, identified as 
a master regulator of epidermal differentiation, restricts stem-
ness by targeting and suppressing expression of the stem cell-
marker p63 (Yi et al., 2008).
 miRNAs with roles in skin development have also been 
identified in disease states that involve impaired tissue 
homeostasis (Figure 5). Recently, a study by Noguchi and 
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Figure 4.  3′ Untranslated region (3′ UTR) luciferase assay to validate the 
interaction between a microRNA and its target 3′ UTR.  MicroRNA mimics 
and a vector containing a chimeric reporter gene consisting of luciferase 
fused to the 3′ UTR for a specific gene of interest are introduced into cells 
by transfection. (A) If the microRNA does not interact with the transcript, 
translation and subsequent production of the protein product occur. The 
luciferase product may then be detected with a luminometer. (B) If the 
microRNA specifically targets the transcript through complementary base 
pairing, then luciferase protein product is not produced. Thus, little or 
no luciferase signal is detected, representing an interaction between the 
microRNA and the 3′ UTR.
colleagues identified and characterized the role of miR-203 
in malignant melanoma. Following a miRNA profiling array 
that identified decreased miR-203 expression in human and 
canine malignant melanoma samples (Noguchi et al., 2013), 
the group defined a role for this miRNA in melanocyte biol-
ogy, specifically in melanosome transport and melanogen-
esis (Noguchi et al., 2014). The study confirmed that miR-203 
acts as a tumor suppressor by demonstrating its ability to neg-
atively influence the proliferation of two human melanoma 
cell lines, Mewo and A2058, after the miRNA was introduced 
into the cell by transfection (Figure 6a). Furthermore, miR-
203 transfection induced pigmentation of the cells (Figure 
6b and c), which led to the hypothesis that miR-203 impacts 
melanogenesis via melanosome transport mechanisms. The 
computational miRNA target prediction algorithm TargetScan 
was used to predict the candidate targets of miR-203, and this 
analysis suggested that members of the kinesin family (kifs), 
responsible for intracellular transport of melanosomes, were 
targets of miR-203. To validate these predicted targets, lucif-
erase assays were performed in which miR-203 significantly 
suppressed luciferase activities when the 3′ UTR of kif2a or 
kif5b was present (Figure 6e). To confirm the specificity of the 
interaction, mutation of the putative miRNA-binding region 
within the target 3′ UTR markedly abolished the effect of 
miR-203 (Figure 6e). These findings indicate that miR-203 
modulates kinesin production, at both the mRNA and protein 
levels, effects that were reversed by anti-miR-203 (Figure 6c, 
d, and f). Results from this study suggest that miR-203 plays 
a pivotal role in melanoma development, and future experi-
mental efforts will provide further insight into the functional 
role of this and other miRNAs in the melanoma setting.
FUTURE POTENTIAL FOR miRNAS IN DERMATOLOGY
Although miRNAs have been best characterized in mela-
noma (Poliseno et al., 2012; Fleming et al., 2014), their 
roles in the skin extend beyond the field of cancer biology. 
miRNAs have also been implicated in psoriasis, atopic ecze-
ma, and Sézary syndrome (Sonkoly et al., 2007; Ballabio et 
al., 2010; Guinea-Viniegra et al., 2014). With the advance-
ment of the field, we will better understand how miRNAs 
regulate these processes. Increased understanding of mRNAs’ 
contribution to disease will aid in the development of 
miRNA-targeted therapy in the future, as well as exploitation of 
miRNAs as clinical biomarkers. Yet, many therapeutic 
challenges remain: therapeutic delivery, instability, and 
non-specificity. miRNA therapy, which targets an array of 
Figure 5.  Breakthrough discoveries in miRNA biology.   The timeline focuses 
on the field of dermatology. 
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different gene products, carries with it the possibility of 
off-target, undesired, and nonphysiological effects. As we 
tackle future challenges, scientists may be able to therapeu-
tically modulate pathogenesis by way of miRNAs or their 
antagomiRs. The future seems bright with the recent promis-
ing work of scientists who have successfully controlled pso-
riasis in murine models with such oligonucleotides (Guinea-
Viniegra et al., 2014), and therapeutic delivery of miRNA 
mimics or antagomiRs has entered human clinical trials for 
cancer and other diseases (https://clinicaltrials.gov). miRNAs 
hold considerable promise as biomarkers of dermatologic 
diseases in addition to their potential as tiny “magic bullets” 
to normalize gene expression in an array of skin pathologies.
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Figure 6.  miR-203 regulates kinesin at the miRNA and protein levels.    
(a) Exogenous miR-203 suppressed the growth of melanoma cells. (b) Mewo 
cells stained with Masson–Fontana ammoniacal silver stain shows increased 
pigmentation. Bar = 20 μm. (c) Expression levels of various proteins by 
western blotting. Melan-A (Melanoma-antigen), HMB45 (melanosome 
marker), TYR (tyrosinase), kif (kinesins). (d) mRNA expression levels of kif2a 
and kif5b in Mewo cells were downregulated by exogenous miR-203. (e) 
Relative luciferase activities after cotransfection with control miR or miR-203 
and each of the sensor vectors having the 3′-untranslated region of kif2a or 
kif5b. (f) Expression levels of various proteins by western blotting. The assays 
were performed at 96 (Mewo) or 72 (A2058) hours after the transfection. 
Values were determined for differences between the cells transfected with 
control miR and those transfected with miR-203 inhibitor. Data are expressed 
as the mean + SD (n = 3). Cont, control. *P < 0.05 and **P < 0.01. Adapted 
from Noguchi et al. (2014).
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1. What is the typical length of miRNA nucleotides 
 and its SEED sequence?
 A. 22; 7. 
 B. 40; 22.
 C.  7; 22.
 D.  8; 7.
2.  miRNA regulation involves which level(s) of control?
 A.  DNA replication.
 B.  mRNA destabilization.
 C. Protein repression.
 D.  Both B and C.
3.  Describe the mechanism of action of miRNAs.
 A.  miRNAs use adapter proteins to interfere with 
replication.
 B. miRNAs cause destabilization of mRNA 
  and inhibit translation initiation. 
 C.  miRNAs usurp the polymerase II machinery to 
decrease its activity and lower the levels of the 
endogenous mRNA. 
 D.  miRNAs rely on anti-microRNAs to potentiate 
their effects.
4.  The best assay to identify whether a specific miRNA 
targets a particular transcript is which of the 
following?
 A.  PCR.
 B. Western blot.
 C. MicroArray.
 D. Luciferase assay.
5.  When a specific miRNA interacts with its target 
3′ UTR in a luciferase assay, the reporter signal
 A. Increases.
 B. Decreases.
 C. Stays the same.
QUESTIONS
This article has been approved for 1 hour of Category 1 CME credit.  
To take the quiz, with or without CME credit, follow the link under  
the “CME ACCREDITATION” heading.
For each question, more than one answer may be correct.
© 2015 The Society for Investigative Dermatology www.jidonline.org 5
research Techniques made simple  
Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene 
lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 
75:843–54
Lee Y, Ahn C, Han J et al. (2003) The nuclear RNase III Drosha initiates 
microRNA processing. Nature 425:415–9
Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked 
by adenosines, indicates that thousands of human genes are microRNA 
targets. Cell 120:15–20
Nambudiri VE, Widlund HR (2013) Small interfering RNA. J Invest Dermatol 
133:e15
Noguchi S, Mori T, Hoshino Y et al. (2013) MicroRNAs as tumour suppressors 
in canine and human melanoma cells and as a prognostic factor in canine 
melanomas. Vet Comp Oncol 11:113–23
Noguchi S, Kumazaki M, Yasui Y et al. (2014). MicroRNA-203 regulates 
melanosome transport and tyrosinase expression in melanoma cells by 
targeting kinesin superfamily protein 5b. J Invest Dermatol 134:461–9
Poliseno L, Haimovic A, Segura MF et al. (2012) Histology-specific microRNA 
alterations in melanoma. J Invest Dermatol 132:1860–8
Sonkoly E, Wei T, Janson PC et al. (2007) MicroRNAs: novel regulators 
involved in the pathogenesis of psoriasis? PLoS One 2:e610
Webster RJ, Giles KM, Price KJ et al. (2009) Regulation of epidermal growth 
factor receptor signaling in human cancer cells by microRNA-7. J Biol 
Chem 284:5731–41
Yi R, O’Carroll D, Pasolli HA et al. (2006) Morphogenesis in skin is governed 
by discrete sets of differentially expressed microRNAs. Nat Genet 
38:356–62
Yi R, Poy MN, Stoffel M et al. (2008) A skin microRNA promotes 
differentiation by repressing “stemness.” Nature 452:225–9
Yi R, Pasolli HA, Landthaler M et al. (2009) DGCR8-dependent microRNA 
biogenesis is essential for skin development. Proc Natl Acad Sci USA 
106:498–502
